The shell is the A54 peptide inserted into RBCm (AR); In particular, AR-NADR can induce a trio of synergetic effects: (i) the dual-targeting effects of the NLS and A54 peptide guide the AR-NADR to the HCC cell nucleus; (ii) the camouflage provided by the RBCms imparts good immune escape ability as well as biocompatibility; and (iii) the downregulation of NOR1 can reverse cisplatin resistance by reducing drug elimination. The gene discussed is OSCP1; the disease is hepatocellular carcinoma.